Impact of ATO on the outcome of newly diagnosed APL with different conventional risks. (A) Impact of ATO-containing induction (ATRA/IV-ATO and oral-AAA) on RFS compared with ATRA/chemotherapy induction in patients with low/intermediate-risk disease. (B) Impact of ATRA/chemotherapy/ATO maintenance, ATRA/IV-ATO, and frontline oral-AAA groups on RFS compared with ATRA/chemotherapy/non-ATO maintenance in patients with low/intermediate-risk disease. (C) Impact of ATO-containing induction (ATRA/IV-ATO and oral-AAA) on 60-day survival compared with the ATRA/chemotherapy induction in patients with high-risk disease. (D) Impact of ATO-containing induction (ATRA/IV-ATO and oral-AAA) on RFS compared with ATRA/chemotherapy induction in patients with high-risk disease. (E) Impact of ATRA/chemotherapy/ATO maintenance, ATRA/IV-ATO, and frontline oral-AAA groups on RFS compared with ATRA/chemotherapy/non-ATO maintenance in patients with high-risk disease.